Waldhoer Thomas, Berger Ingrid, Haidinger Gerald, Zielonke Nadine, Madersbacher Stephan
Department of Epidemiology, Centre of Public Health, Medical University of Vienna, Wiener Neustadt, Austria.
Urol Int. 2015;94(4):383-9. doi: 10.1159/000368418. Epub 2015 Mar 28.
In recent days, the relationship between gender, tumour stage and survival of bladder cancer has attracted interest.
The Austrian cancer registry was linked to the national death statistics. All patients with urothelial cancer of the urinary bladder with stages pT1, pT2, pT3 and pT4 diagnosed between 1983 until 2012 were followed for up to 15 years. Overall and cancer-specific mortality were estimated by cumulative incidence.
A total of 27,773 patients were analysed. The male:female ratio declined from 3:1 for stage pT1-tumours (n = 16,416) to 2.6:1 for pT2 (n = 6,548), 2.1:1 for pT3 (n = 3,111) and 1.9:1 for pT4 (n = 1,698). The 5 years cumulative overall death rate for pT1 tumours was slightly lower for women (0.31 vs. 0.32; p = 0.016). The opposite was observed for more advanced tumour stages: pT2: women 0.66, men: 0.60 (p = 0.0001); pT3: women 0.76, men 0.72 (p = 0.0004) and for pT4: women 0.90, men 0.85 (p = 0.0001). Cancer-specific survival was identical for pT1-tumours in both sexes, while women had a worse cancer-specific survival in both age cohorts (<70 years and ≥70 years) with higher tumour stages.
This population-based study demonstrates that (1) a rise of advanced bladder cancer stages in women and (2) that women with tumour stages >pT1 have a shorter cancer-specific and overall survival.
近年来,膀胱癌的性别、肿瘤分期与生存率之间的关系引起了关注。
奥地利癌症登记处与国家死亡统计数据相关联。对1983年至2012年间诊断为pT1、pT2、pT3和pT4期的所有膀胱尿路上皮癌患者进行了长达15年的随访。通过累积发病率估计总死亡率和癌症特异性死亡率。
共分析了27773例患者。男性与女性的比例从pT1期肿瘤的3:1(n = 16416)下降到pT2期的2.6:1(n = 6548)、pT3期的2.1:1(n = 3111)和pT4期 的1.9:1(n = 1698)。pT1期肿瘤的5年累积总死亡率女性略低(0.31对0.32;p = 0.016)。在更晚期肿瘤分期中观察到相反的情况:pT2期:女性0.66,男性0.60(p = 0.0001);pT3期:女性0.76,男性0.72(p = 0.0004);pT4期:女性0.90,男性0.85(p = 0.0001)。pT1期肿瘤的癌症特异性生存率在两性中相同,而在肿瘤分期较高的两个年龄组(<70岁和≥70岁)中,女性的癌症特异性生存率较差。
这项基于人群的研究表明,(1)女性晚期膀胱癌分期增加,(2)肿瘤分期>pT1的女性癌症特异性生存率和总生存率较短。